Risk of variant Creuzfeldt-Jakob disease from factor concentrates: Current perspectives

Haemophilia

Volumn 8, Issue 3, 2002, Pages 230-235

  Farrugia, A ^a,b,c  

^a Australian Commonwealth Department of Health and Aged Care ^*  (Canada)

^b WORLD FEDERATION OF HEMOPHILIA   (Canada)

^c THERAPEUTIC GOODS ADMINISTRATION   (Australia)

Author keywords

Factor concentrates; Haemophilia; Transmissible spongiform encephalopathies; Variant Creutzfelt Jakob disease

Indexed keywords

BLOOD CLOTTING FACTOR; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD COMPONENT THERAPY; BLOOD DONOR; BOVINE SPONGIFORM ENCEPHALOPATHY; CATTLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; DRUG SAFETY; EPIDEMIOLOGY; EUROPE; FOOD AND DRUG ADMINISTRATION; FRACTIONATION; HEMOPHILIA; HUMAN; IATROGENIC DISEASE; INFECTION RISK; LABORATORY TEST; MEAT; NANOFILTRATION; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; UNITED KINGDOM; HEMOPHILIA A; REVIEW; RISK;

BLOOD COAGULATION FACTORS; BLOOD COMPONENT TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; HEMOPHILIA A; HUMANS; RISK;

EID: 0036588695     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00618.x     Document Type: Article

References (32)

1. Prusiner SB. Prions. PNAS 1998; 95: 13363-83.
2. Ricketts MN, Cashman NR et al. Is Creuzfeldt-Jakob disease transmitted in blood? Emerging Inf Dis 1997; 3: 155-63.
3. European Commission. Communication from the Commission on the Precautionary Principle. URL: http://europa.eu.int/comm/dgs/health_consumer/library/pub/pub07.pdf, 2000.
4. HIV and the Blood Supply: An Analysis of Crisis Decision-making. Washington DC: National Academy Press, 1985.
5. Report of the Krever Commission of Inquiry into the Blood System in Canada, 1996.
6. Menache D, O'Malley JP. Creuzfeldt-Jakob disease: Current US Policy to further reduce the possible risk of transmission by transfusion. Biologicals 1996; 24: 277-83.
7. Wilson K, Code C, Ricketts M. Risk of acquiring Creuzfeldt-Jakob disease from blood transfusions. Systematic review of case-controlled studies. BMJ 2000; 321: 17-9.
8. Center for Biologics Evaluation and Research. Change to the Guidance Entitled 'Revised Precautionary Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) by Blood and Blood Products. URL: http://www.fda.gov/cber/infosheets/cjdchange.htm.
9. Will RG, Ironside JW et al. A new variant of Creuzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5.
10. Scott MR, Will R et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy to humans. PNAS 1999; 96: 15137-42.
11. Hill AF, Zeidler M et al. Diagnosis of new variant Creuzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99-100.
12. Taylor DM, Fernie K, Reichl HE, Somerville RA. Infectivity in the blood of mice with a BSE-derived agent. J Hosp Infect 2000; 46: 78-9.
13. Houston F, Foster JD, Ching A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1000.
14. Baron H. Theoretical risk of CJD transmission through blood or blood products - what is known and what is needed? Presented at 'Prions: Assessment and Management of Risks from Blood-Borne TSE Infectivity'. IBC USA Conferences Inc., 2001.
15. Centre for Biologics Evalution and Research. Revised Precautionary Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and New Variant Creutzfeldt-Jakob Disease (nvCJD) by Blood and Blood Products URL: http://www.fda.gov/cber/gdlns/cjdnvcjd.pdf.
16. American Red Cross. American Red Cross Implements New Deferral Policy URL: http://www.redcross.org/press/biomed/bm_pr/011012deferpol.html, 2001.
17. Centre for Biologics Evalution and Research. Transcript of the TSE Advisory Committee Meeting of 18 January 2001 URL: http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3681t1.rtf, 2001.
18. Centre for Biologics Evalution and Research. Transcript of the TSE Advisory Committee Meeting of 28 June 2001 URL: http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3762t1.rtf, 2001.
19. Centre for Biologics Evalution and Research. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products - Draft Guidance URL: http://www.fda.gov/cber/gdlns/cjdvcjd.pdf, 2001.
20. Phillips Report into the BSE Inquiry in the UK URL: http://www.bseinquiry.gov.uk/report/volume10/chaptef2.htm#260106, 2000.
21. Brown P, Cervenakova L et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-78.
22. Hill AF, Joiner S et al. Species barrier-independent prion replication in apparently resistant species. PNAS 2000; 97: 10248-53.
23. Brown P, Cervenakova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creuzfeldt-Jakob disease.
24. MacGregor I. Prion protein and developments in its detection. Trans Med 2001; 11: 3-14.
25. Schmerr MJ, Jenny A et al. Use of capillary electrophoresis and fluourescent labelled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy. J Chromatogr A 1999; 853: 207-14.
26. Safar J, Wille H et al. Eight prion strains have PrPSc molecules with different conformations. Nature Med 1998; 4: 1157-65.
27. MacGregor I, Hope J et al. Application of a time-resolved fluorimmunoassay for the analysis of normal prion protein in human blood and its components. Vox Sanguinis 1999; 77: 88-96.
28. Dodd R. Comment During Public Meeting 'Can the Public Health Service Bovine Spongiform Encephalopathy/Transmissible Spongiform Encephalopathy (bse/tse) Action Plan be Expanded to Capitalize on the Human and Physical Resources of the Pharmaceutical and Biotechnology Industries?' URL: http://www.hhs.gov/bloodsafety/transcripts/20010924.html.
29. Taylor DM. 1999 Inactivation of prions by physical and chemical means. J Hosp Infection 2001; 43 (Suppl.): 569-76.
30. Lee DC, Stenland CJ et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001; 41: 449-55.
31. Petteway S. Partitioning of Transmissible Spongiform Encephalopathy (TSE) by Plasma or Biotechnology Manufacturing Processes Presented at 'The policies and science of prions and plasma workshop', Washington DC, 23-24 October 2001.
32. Rothschild C, Alcalay M, Macchi L et al. Factor VIII SD-35-15: efficacy and safety clinical data with solvent-detergent treated and 35-15 nm filtered factor VIII concentrate. Thromb Haemost 2001; 46(2): Abstract 2871.